4-anilino quinazoline derivatives as antiproliferative agents
申请人:Bradbury Hugh Robert
公开号:US20050215574A1
公开(公告)日:2005-09-29
The invention concerns quinazoline derivatives of Formula (I) wherein each of Q
1
, Z, R
1
and Q
2
have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS
申请人:Bradbury Robert Hugh
公开号:US20080269487A1
公开(公告)日:2008-10-30
The invention concerns quinazoline derivatives of Formula (I) wherein each of Q
1
, Z, R
1
and Q
2
have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
The invention concerns quinazoline derivatives of Formula I
wherein each of Q
1
, Z, R
1
and Q
2
have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
[EN] 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS<br/>[FR] DERIVES DE 4-ANILINO QUINAZOLINE UTILISES EN TANT QU'AGENTS ANTIPROLIFERATIFS
申请人:ASTRAZENECA AB
公开号:WO2003082831A1
公开(公告)日:2003-10-09
The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.